Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Technical analysis for shorts & longs -- Ignore unavailable to you. Want to Upgrade?

To: Michael Rich who wrote (15147)	1/25/1998 2:17:00 PM
From: Judy	Respond to of 68045

Good morning, Mikey Proper entry for IMNX may be here soon. Stock hovering about its 200-day ema, earnings Feb 4th, analysts ready to pounce, BMY has filed suit against company. Any insights to add to this? ************************* Wednesday, January 21, 1998 06:30 PM SEATTLE -- Immunex Corporation (Nasdaq:IMNX) confirmed today that, as expected, a complaint has been filed by Bristol-Myers Squibb Company (NYSE:BMY) in the U.S. District Court in Newark, New Jersey, alleging infringement by Immunex of two U.S. patents pertaining to the product Taxol(R). Immunex filed an abbreviated new drug application (ANDA) in August 1997 requesting U.S. Food and Drug Administration approval for its competitive product to Taxol. In its ANDA, Immunex certified that the Bristol-Myers patents are invalid and not infringed by the Immunex ANDA.